IMGT/mAb-DB card

INN amendment: epcoritamab INN structure is that amended in L123 proposed list (2020) and published in R84 recommended list (2020).
INN amendment: epcoritamab INN description is that amended in L127 proposed list (2022) and published in R88 recommended list (2022).

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract

IMGT/mAb-DB ID	949
INN	epcoritamab
INN Number	11078
INN Prop. List	121 (2019)
INN Rec. List	83 (2020)
Common name	GEN3013
Proprietary name
Species	Homo sapiens Chimeric
IMGT receptor type	IG
Format (legend)
Receptor identification	Ig(G1 - kappa_G1 - lambda2)
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB	11078
IMGT/3Dstructure-DB
Specificity target name and species	CD3E (CD3e, CD3 epsilon) [Homo sapiens, Chimeric] MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens, Chimeric] bispecific [Homo sapiens, Chimeric]
Development Technology
Origin clone species
Origin clone name

Company	Genmab A/S (Copenhagen Denmark)
Expression system	CHO (Chinese Hamster Ovary) cells
Application	Therapeutic
Clinical domain	Oncology
Mechanism of action
Clinical indication	B-cell malignancies
Development status
Regulatory agency status and year

Clinical trials	1 studies found, 1 recruiting
Authority decisions
External links
IMGT notes	INN amendment: epcoritamab INN structure is that amended in L123 proposed list (2020) and published in R84 recommended list (2020). INN amendment: epcoritamab INN description is that amended in L127 proposed list (2022) and published in R88 recommended list (2022).
Biosimilars

Format legend:

IMGT/mAb-DB query | IMGT/mAb-DB documentation